Themis Bioscience is a Vienna-based company with a focus on utilizing technology that it has developed to advance vaccine candidates for various infectious diseases. The company states that its Themaxyn platform allows for researchers to rapidly identify and develop vaccines.
The company worked in collaboration with the Pasteur Institute during the COVID-19 pandemic. The role of Themis Bioscience was to provide scaling and manufacturing services once its partners had developed and tested a vaccine. The time frame for when the manufacturing will take place is unknown.
CEPI issued an urgent call for $2 billion of new funding to enable the organisation to expand the number of COVID-19 vaccine candidates in development and to fund the clinical trials for these candidate vaccines.
CEPI, the Coalition for Epidemic Preparedness Innovations, today added an eighth COVID-19 vaccine candidate to its portfolio. CEPI will invest an initial US$4.9 million in a partnering agreement with the Institut Pasteur-led consortium that will include Themis and the University of Pittsburgh to develop a vaccine candidate against COVID-19.
Dr. Erich Tauber
Austrian Vaccine Developer Signs Deal with MSD in 'Blockbuster Indication'
Clara Rodriguez Fernandez
August 22, 2019
Themis and Institut Pasteur Join Coronavirus Vaccine Hunt
March 20, 2020
Documentaries, videos and podcasts
BIO-Europe Spring 2019: Themis Bioscience Harnesses Measles Vector For Immune Modulation
May 22, 2019
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.